A review: Mechanism and prospect of gastrodin in prevention and treatment of T2DM and COVID-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Revealing the potential of Gastrodia elata as a therapeutic candidate for degenerative diseases.Journal, genetic engineering & biotechnology · 2026
   Article
2. Gastrodin alleviates myocardial infarction by inhibiting inflammation, and apoptosis and promoting endothelial cell proliferation.Biochemistry and biophysics reports · 2025
   Article
3. Gastrodin Alleviates Angiotensin II-Induced Hypertension and Myocardial Apoptosis via Inhibition of the PRDX2/p53 Pathway In Vivo and In Vitro.Pharmaceuticals (Basel, Switzerland) · 2024
   Article
4. Gastrodin improves osteoblast function and adhesion to titanium surface in a high glucose environment.Biochemistry and biophysics reports · 2024
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as